Tebapivat by Agios Pharmaceuticals for Sickle Cell Disease: Likelihood of Approval

Tebapivat is under clinical development by Agios Pharmaceuticals and currently in Phase I for Sickle Cell Disease.

Make the Diagnosis: He Has Facial Lesions—and So Do Some Teammates. What’s Up?

Presentation A 17-year-old mixed martial arts athlete presented to the doctor with complaints of facial lesions that developed 4 days prior. On examination, discrete and

November 27, 2024

23andMe board rejects CEO Wojcicki’s take-private proposal

A special committee of 23andMe’s board of directors said Friday it was “disappointed” in a proposal by CEO Anne Wojcicki to take the company private.

August 2, 2024

Exclusive: PhRMA attacks federal government’s response to rebate model for 340B

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.